D. Allen Annis

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Yong S. Chang, Bradford Graves, Vincent Guerlavais et al. · Proceedings of the National Academy of Sciences · 2013 · 661 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Polymer-Supported Chiral Co(Salen) Complexes:  Synthetic Applications and Mechanistic Investigations in the Hydrolytic Kinetic Resolution of Terminal Epoxides

D. Allen Annis, Eric N. Jacobsen · Journal of the American Chemical Society · 1999 · 426 citations

Natural Sciences, Chemical Engineering, Chemistry +15

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

Daniela Ben Neriah, Adrien Senecal, Lumie Benard et al. · Science Translational Medicine · 2018 · 250 citations · Full text

Medicine, Oncology, Pharmacology +15

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Xiaolei Zhou, Madhurendra Singh, Gema Sanz et al. · Cancer Discovery · 2021 · 174 citations · Full text

Medicine, Immunology, Oncology +17

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer et al. · Clinical Cancer Research · 2021 · 147 citations · Full text

Medicine, Oncology, Pharmacology +17